Price movement over the last 24 hours
ADMA Biologics Inc vs Ishares Msci Spain ETF — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Ishares Msci Spain ETF trades at $58.77. The key difference: Ishares Msci Spain ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWP | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $60.28 |
52-Week Low | $7.60 | $43.48 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
EWP trades at $60.28, up 1.04% today, with strong bullish technical signals from moving averages and a neutral RSI. The stock shows momentum above key support levels. Recent news highlights European market strength, with Spain's GDP outperforming the Eurozone, potentially benefiting EWP's regional exposure. A dividend of $0.92 is scheduled for June 2026, adding income appeal.
Outlook is cautiously optimistic due to technical strength and positive European economic trends, but fundamental data is limited. Risks include European regulatory probes and energy price volatility. Investors should monitor upcoming financial disclosures for valuation clarity amid current data gaps.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →